This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 9.40%. For Cencora, estimates have been trending higher, thanks in part to this earnings surprise history. And when you The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related ...

Professor Tim Jackson, PhD, FRCOphth, Consultant Ophthalmic Surgeon, King's College Hospital and Professor of Retinal Research, King's College London, commented, "We have waited a long time for a brand of bevacizumab that is authorized for eye use, and it is good news that LYTENAVA™ has now entered the market. This occurs subsequent to Outlook Therapeutic's clinical trial meeting its endpoint. To date, many ophthalmologists have been hesitant to use an off-label bevacizumab, when licensed products are avail ...

Cencora's shares have risen 11% year to date compared with the industry's growth of 4.1%. the S&P 500 Index has increased 15.2% in the same period. Per a CNN article, the recent Supreme Court ruling invalidated the $6 billion settlement related to the primary alleged entity in opioid abuse litigation, Purdue Pharma, which would have shielded its owner, the Sackler family, from future financial claims. Moreover, four states opted not to join the national settlement in 2021 and were able to continue their leg ...

1 IF D H HT T 100 - 100 1 i T 1 Pgiam/iStock via Getty Images Investment Update Since my last publication on Cencora (NYSE:COR) shares have continued to advance and now trade 13% higher. This marks a substantial gain from the original buy thesis I presented on COR in 2023. Analysts in a Bernstein-Societe Generale rated COR a high-quality stock with high ROIC trading at sensible valuations in a recent analysis. This is exactly the sentiment I have held with COR since day on, and this has not changed. Earning ...

The rally in the company's share price can be attributed to the robust growth in the company's U.S. Healthcare Solutions segment. The optimism led by a solid second-quarter fiscal 2024 performance and robust business potential are expected to contribute further. Cencora exited second-quarter fiscal 2024 with decent results. The company witnessed solid top-line and bottom-line performances in the reported quarter, which is likely to have aided in the price growth. In the fiscal second quarter, Cencora's U.S. ...

Cencora, Inc. (COR) is well-poised for growth on the back of robust U.S. Healthcare Solutions business and product launches. However, intense competition is a concern. COR currently reports under two segments — U.S. Healthcare Solutions and International Healthcare Solutions. The first segment comprises the legacy Pharmaceutical Distribution Services (excluding Proforma), MWI Animal Health, Xcenda, Lash Group and ICS 3PL. It benefits from an increasing volume and expanding customer base. Strong organic grow ...

Walgreens has sold more shares of drug distributor Cencora for proceeds of about $400 million, which ... [+] will be used for "debt paydown and general corporate purposes."In this 2013 photo, a sign marks the entrance to a Walgreens store in San Francisco's upscale Union Square shopping district. (Photo by Robert Alexander/Getty Images) Getty Images The stock sale, which comes as chief executive officer Tim Wentworth works on a financial turnaround of the iconic drugstore chain, brings Walgreens stake in Ce ...

For the quarter ended March 2024, Cencora (COR) reported revenue of $68.41 billion, up 7.8% over the same period last year. EPS came in at $3.80, compared to $3.50 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $70.35 billion, representing a surprise of -2.75%. The company delivered an EPS surprise of +4.11%, with the consensus EPS estimate being $3.65.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual amounts could differ from these estimated amounts. Certain reclassifications have been made to prior-period amounts in order to conform to the current year presentation. The purchase price exceeded the estimated fair value of the net tangible and intangible assets acquired by $1,010.2 million, which ...

Cencora, Inc. (NYSE:COR) Q2 2024 Earnings Call Transcript May 1, 2024 8:30 AM ET Company Participants Bennett Murphy - SVP, Head of IR and Treasury Steve Collis - Chairman, President, and CEO Bob Mauch - EVP and COO Jim Cleary - EVP and CFO Conference Call Participants Elizabeth Anderson - Evercore Lisa Gill - JPMorgan Daniel Grosslight - Citi Eric Percher - Nephron Research Allen Lutz - Bank of America Stephanie Davis - Barclays Charles Rhyee - TD Cowen Michael Cherny - Leerink George Hill - Deutsche Bank ...